玄延花，女，朝鮮族，博士，延邊大學醫學院教授、博士生導師、教研室主任。曾任韓國忠北大學博士後研究員、韓國三星漢城醫院訪問學者。
研究方向為腫瘤侵襲轉移機制。
基本介紹
人物經歷,學習經歷,工作經歷,榮譽獎項,教育教學,承擔課程,承擔課題,著作教材,課程建設,科學研究,科研課題,科研論文,
人物經歷
學習經歷
1.1992/09–1997/07，延邊大學醫學院，臨床醫學專業，學士學位
2.1997/09–2000/07，延邊大學醫學院，病理學與病理生理學專業，碩士學位
3.2001/09–2005/02，韓國忠北大學醫科大學，病理學專業，博士學位
工作經歷
1.2000/07－2006/06，延邊大學醫學院，病理學教研室，助教
2.2005/03－2005/08，韓國忠北大學醫科大學，病理學教室，博士後研究員
3.2006/07－2006/12，延邊大學醫學院，病理學與法醫學教研部，講師
4.2007/01－2018/08，延邊大學醫學院，病理學與法醫學教研室，副教授
5.2012/02–2013/02，韓國三星漢城醫院生命科學研究所，訪問學者
6.2018/09–，延邊大學醫學院，病理學與法醫學教研室，教授
榮譽獎項
1.玄延花，Yoon-la Choi, Young kee Shin, Geung hwan Ahn, Kyung hee Kim, Wun jae Kim, Ho Chang Lee, Seok hyung Kim. Expression of TGFβ signaling proteins in normal placenta and gestational trophoblastic disease. 吉林省第七屆自然科學學術成果三等獎，2009年（2009C-073）
2. 玄延花，金錫亨，林貞花. 在膀胱移形細胞癌中CD99蛋白表達與基因啟動子甲基化. 吉林省自然科學學術成果三等獎，2013年(20133106)
3.玄延花,崔演,林貞花,孫鳳丹,任香善. Hedgehog信號通路對宮頸癌的病理學意義. 吉林省科學技術獎三等獎, 2015年（2015Z30011）
4. 楊昭婷，呂曉瑩，尹永學，林貞花，李學敏，玄延花*，崔 演，金錫亨. Tenascin-C在食管鱗癌預後中的判定價值. 吉林省自然科學學術成果三等獎，2017年（20173113）
5. 玄延花,崔演,楊昭婷，倪衛東，崔春愛，方龍雲，金昱. Gli1調控的腫瘤微環境與乾性特徵對腫瘤預後的作用. 吉林省科學技術獎二等獎, 2020年（2020Z20018）
教育教學
承擔課程
1.《病理學》，本科生課程，專業核心課
2.《疾病探究》，本科生課程，通識教育課
3.《組織病理學》，研究生課程，專業核心課
承擔課題
翻轉課堂教學模式在病理學實習教學中的套用, 吉林省高等教育學會，2017年度高教科研課題，JGJX2017D24，2017.01-2019.12
著作教材
1.《新圖解病理學》，鄭州大學出版社，2018年，主譯
2.《臨床腫瘤學》，出版社，2014年，副主編
課程建設
《口腔組織病理學》課程，校級優秀課程，2015，延邊大學，課程負責人
科學研究
科研課題
1.阻斷Hedgehog信號通路對宮頸癌侵襲和轉移的作用；國家自然科學基金 (2010.01-2012.12) (No. 30960403), 24.0萬元，主持
2.Hedgehog信號通路調控宮頸癌上皮間質轉化的作用及機制；國家自然科學基金 (2012.01-2015.12) (No. 81160315), 46.0萬元，主持
3.Hedgehog-Gli1信號通路調控Nanog參與宮頸癌幹細胞自我更新中的作用及機制研究；國家自然科學基金 (2015.01-2018.12) (No. 81460390), 47.0萬元，主持
4.Gli1對口腔種植體周圍炎的作用及機制；吉林省教育廳“十三五”科學技術研究項目（2016.01-2017.12）（No.吉教科合字[2016]第266號），3萬元，主持
5.NFκB介導的Gli1對食管癌幹細胞特性的作用及機制研究；國家自然科學基金 (2018.01-2021.12) (No. 81760531), 34.0萬元，主持
6.氧化鈰/鉑納米顆粒介導腫瘤乾性特徵與M2型巨噬細胞極化調節食管癌順鉑耐藥的作用機制；國家自然科學基金 (2022.01-2025.12) (No. 82160594), 34.1萬元，主持
科研論文
1.Yang ZT, Yeo SY, Yin YX, Lin ZH, Lee HM, Xuan YH*（通訊作者）, Cui Y, Kim SH. Tenascin-C, a Prognostic Determinant of Esophageal Squamous Cell Carcinoma. PLoS One. 2016,11(1).
2.Yang Z, Cui Y, Ni W, Kim S, Xuan Y*（通訊作者）. Gli1, a potential regulator of esophageal cancer stem cell, is identified as an independent adverse prognostic factor in esophageal squamous cell carcinoma. J Cancer Res Clin Oncol. 2017,143(2):243-254.
3.Zhao-Ting Yang, Wei-Dong Ni, Xin-Xin Liu, Yan-Hua Xuan*（通訊作者）, Yu-Jin. Tenascin-C is a diagnostic marker for cervical cancer and a potential marker for cancer-associated fibroblasts in cervical carcinoma. Int J Clin Exp Pathol. 2017,10(1):139-147.
4.Yang Z, Ni W, Cui C, Fang L, Xuan Y*（通訊作者）. Tenascin C is a prognostic determinant and potential cancer-associated fibroblasts marker for breast ductal carcinoma. Exp Mol Pathol. 2017,102(2):262-267.
5.Wei-Dong Ni, Zhao-Ting Yang, Chun-Ai Cui, Yan Cui, Long-Yun Fang, Yan-Hua Xuan*（通訊作者）. Tenascin-C is a potential cancer-associated fibroblasts marker and predicts poor prognosis in prostate cancer. Biochem Biophys Res Commun. 2017, 486(3):607-612.
6.Yan Cui, Chun-ai Cui, Zhao-ting Yang, Wei-dong Ni, Yu Jin, Yan-hua Xuan*（通訊作者）. Gli1 expression in cancer stem- like cells predicts poor prognosis in patients with lung squamous cell carcinoma. Exp Mol Pathol. 2017,102(2):347-353.
7.So-Young Yeo, Sang-Yun Ha, Keun-Woo Lee, Yan Cui, Zhao-Ting Yang, Yan-Hua Xuan*（通訊作者）, Seok-Hyung Kim. Twist1 is highly expressed in cancer-associated fibroblasts of esophageal squamous cell carcinoma with a prognostic significance. Oncotarget. 2017,8(39):65265-65280.
8.Ni W, Yang Z, Qi W, Cui C, Cui Y, Xuan Y*（通訊作者）. Gli1 is a potential cancer stem cell marker and predicts poor prognosis in ductal breast carcinoma. Hum Pathol. 2017,69;38-45.
9.Lan Liu, Zhaoting Yang, Weidong Ni, Yanhua Xuan*（通訊作者）. ADAMTS-6 is a predictor of poor prognosis in patients with esophageal squamous cell carcinoma. Exp Mol Pathol. 2018; 104 (2):134-139.
10.Piao L, Yang Z, Jin J, Ni W, Qi W, Xuan Y*（通訊作者）. B7H4 is associated with stemness and cancer progression in esophageal squamous cell carcinoma. Hum Pathol. 2018, 80:152-162.
11.Yang Z, Ni W, Cui C, Qi W, Piao L, Xuan Y*（通訊作者）. Identification of LETM1 as a marker of cancer stem cells and predictor of poor prognosis in esophageal squamous cell carcinoma. Hum Pathol. 2018, 81:148-156.
12.Yang Z, Zhang C, Qi W, Cui C, Cui Y, Xuan Y*（通訊作者）. Tenascin-C as a prognostic determinant of colorectal cancer through induction of epithelial-to-mesenchymal transition and proliferation. Exp Mol Pathol. 2018,105(2):216-222.
13.Li-Li Lv, Zhao-Ting Yang, Tong-Hui Ma, Yan-Hua Xuan*（通訊作者）. Gli1, a potential cancer stem cell marker, is strongly associated with prognosis in prostate cancer. Int J Clin Exp Pathol. 2018,11(10): 4957-4966.
14.Yang Z, Zhang C, Qi W, Cui Y, Xuan Y*（通訊作者）. GLI1 promotes cancer stemness through intracellular signaling pathway PI3K/Akt/NFκB in colorectal adenocarcinoma. Exp Cell Res. 2018, 373(1-2):145-154.
15.Zhang C, Yuan Y, Fang L, Xuan Y*（通訊作者）. Promotion of osteogenesis by bioactive glass–ceramic coating through the Hedgehog signaling pathway. J Orthop Sci. 2019, 24(4),731-736.
16.Qi W, Yang Z, Li H, Cui Y, Xuan Y*（通訊作者）. The role of Tenascin-C and Twist1 in gastric cancer: cancer progression and prognosis. APMIS. 2019,127(2):64-71.
17.Yang Z, Zhang C, Feng Y, Qi W, Cui Y, Xuan Y*（通訊作者）. Tenascin-C is involved in promotion of cancer stemness via the Akt/HIF1ɑ axis in esophageal squamous cell carcinoma. Exp Mol Pathol. 2019,109,61-68.
18.Piao L, Feng Y, Yang Z, Qi W, Li H, Han H, Xuan Y*（通訊作者）. LETM1 is a potential cancer stem-like cell marker and predicts poor prognosis in colorectal adenocarcinoma. Pathol Res Pract. 2019,215(7).
19.Piao L, Yang Z, Feng Y, Zhang C, Cui C, Xuan Y*（通訊作者）. LETM1 is a potential biomarker of prognosis in lung non-small cell carcinoma. BMC Cancer. 2019,19(1):1-9.
20.Li H, Piao L, Xu D, Xuan Y*（通訊作者）. LETM1 is a potential biomarker that predicts poor prognosis in gastric adenocarcinoma. Exp Mol Pathol. 2020,112,1-11.
21.Piao L, Li H, Feng Y, Yang Z, Kim S, Xuan Y*（通訊作者）. SET domain-containing 5 is a potential prognostic biomarker that promotes esophageal squamous cell carcinoma stemness. Exp Cell Res. 2020, 389(1):111861.
22.Yang Z, Zhang C, Feng Y, Quan M, Cui Y, Xuan Y*（通訊作者）. Tenascin‑C predicts poor outcomes for patients with colorectal cancer and drives cancer stemness via Hedgehog signaling pathway. Cancer Cell Int. 2020,20:122.
23.Piao LH, Li HY, Feng Y, Li XG, Cui Y, Xuan YH*（通訊作者）. Leucine Zipper-EF-Hand Containing Transmembrane Protein 1 Is a Potential Prognostic Biomarker and Promotes Cell Progression in Prostate Cancer. Cancer Manag Res. 2020,12:1649-1660.
24.Qi WB,Yang ZT, Feng Y, Li HY, Che N, Liu L, Xuan YH*（通訊作者）. Gli1 Regulates Stemness Characteristics in Gastric Adenocarcinoma. Diagn Pathol. 2020,15(1):60.
25.Li H, Piao L, Liu S, Cui Y, Xuan Y*（通訊作者）. B7-H4 is a potential prognostic biomarker of prostate cancer. Exp Mol Pathol. 2020,114,104406.
26.Zhang CY, Yang ZT, Dong DL, Jang TS, Knowles JC, Kim HW, Jin GZ, Xuan YH*（通訊作者）. 3D culture technologies of cancer stem cells: promising ex vivo tumor models. J Tissue Eng. 2020, 24(11):2041731420933407.
27.Piao LH, Feng Y, Che N, Li MX, Li XG, Jin Y, Xuan YH*（通訊作者）. SETD8 is a prognostic biomarker that contributes to stem-like cell properties in non-small cell lung cancer. Pathol Res Pract. 2020, 216(12):153258.
28.Piao LH, Che N, Li HY, Li MX, Feng Y, Liu XZ, Kim SH, Jin Y, Xuan YH*（通訊作者）.SETD8 promotes stemness characteristics and is a potential prognostic biomarker of gastric adenocarcinoma. Exp Mol Pathol. 2020,117:104560.
29.Che N, Yang ZT, Liu XZ, Li MX, Feng Y, Zhang CY, Li C, Cui Y, Xuan YH*（通訊作者）. Suppression of LETM1 inhibits the proliferation and stemness of colorectal cancer cells through reactive oxygen species–induced autophagy. J Cell Mol Med. 2021,25(4):2110-2120.
30.Yang ZT, Zhang CY, Che N, Feng Y, Li C, Xuan YH*（通訊作者）. Su(var)3-9, Enhancer of Zeste, and Trithorax Domain-Containing 5 Facilitates Tumor Growth and Pulmonary Metastasis through Up-Regulation of AKT1 Signaling in Breast Cancer. Am J Pathol.. 2021,191(1):180-193.
31.Feng Y, Yang ZT, Zhang CY, Che N, Liu XZ, Xuan YH*（通訊作者）. B7-H4 induces epithelial-mesenchymal transition and promotes colorectal cancer stemness. Pathol Res Pract. 2021,218:15332.
32.Liu X, Li H, Che N, Zheng Y, Fan W, Li M, Li X, Xuan Y*（通訊作者）. HBXIP accelerates glycolysis and promotes cancer angiogenesis via AKT/mTOR pathway in bladder cancer. Exp Mol Pathol. 2021,121:104665.
33.Yang ZT#, Zhang CY#, Liu XZ#, Che N, Feng Y, Xuan YH*（通訊作者）.SETD5 Regulates Glycolysis in Breast Cancer Stem-Like Cells and Fuels Tumor Growth. Am J Pathol. 2022,19(1): S0002-9440(22)00006-2.
34.Qian Y, Liu X, Feng Y, Li X, Xuan Y*（通訊作者）. Tenascin C regulates cancer cell glycolysis and tumor progression in prostate cancer. Int J Urol. 2022,25.
35.Qian Y, Liu X, Feng Y, Li X, Xuan Y*（通訊作者）. Tenascin C regulates cancer cell glycolysis and tumor progression in prostate cancer. Int J Urol. 2022, 25.
36.Li M, Che N, Feng Y, Liu X, Piao L, Xuan Y*（通訊作者）, Jin Y. B7-H4 expression promotes non-small cell lung cancer progression via AMPK/mTOR signaling. Exp Mol Pathol. 2022, 9:104755.
